Image

A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Investigating Overall Survival in Myelodysplastic Syndromes (MDS) Patients Using Investigational Medication

Recruiting
18-81 years
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the overall survival of patients with Myelodysplastic Syndromes (MDS) who have not responded to previous treatments. MDS is a group of disorders caused by poorly formed or dysfunctional blood cells. The study compares two groups: one receiving an investigational medication and the other receiving treatments chosen by their physician.

Participants will undergo various study procedures to monitor their health and response to treatment. These procedures may include blood tests and other assessments to track the effectiveness and safety of the investigational medication.

  • Who can participate: Adults with Myelodysplastic Syndromes (MDS) who have not responded to previous treatments like azacitidine or decitabine may be eligible. Participants should have an ECOG performance status of 0, 1, or 2 and must be willing to follow study requirements.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a treatment chosen by their physician.
Print
Study details
    myelodysplastic syndrome
    MDS
    refractory anemia with excess blasts
    RAEB
    preleukemia
    cancer
    oncology

TX7046

19 February 2024

Contact a study center
Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Please provide your preferred way of contact1234
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.